J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations
This article was originally published in Scrip
Executive Summary
Informa Pharma's Global Director of Content Mike Ward and Scrip Intelligence West Coast Editor Mandy Jackson moderated a roundtable discussion on Jan. 11, the opening day of the 34th Annual J.P. Morgan Healthcare Conference, in San Francisco during which they spoke with eight biotechnology veterans about the state of biotech going into 2016.
You may also be interested in...
Case Studies: How Three Public Companies Financed R&D In A Tough Market
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Need a specific report? 1000+ reports available
Buy Reports